Tech Company Financing Transactions
Rome Therapeutics Funding Round
Arch Venture Partners, GV and Partners Innovation Fund participated in a $50 million Series A capital raise for Rome Therapeutics. The round was announced on 4/28/2020.
Transaction Overview
Company Name
Announced On
4/28/2020
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome -- vast stretches of uncharted genetic material that have long been dismissed as "junk DNA." With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rosana Kapeller
Chief Scientific Officer
Dennis Zaller
Vice President
David Proia
Vice President
Donna Romero
VP - Bus. Development
Wenyan Miao
VP - Finance
Kira Nelson
VP - Operations
Christine Loggins
Browse more venture capital transactions:
Prev: 4/28/2020: LifeSprout venture capital transaction
Next: 4/28/2020: Actym Therapeutics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs